- Allergan Medical Institute (AMI) Training Centers to offer most
comprehensive, training programs accelerating providers'
consultative and clinical skills
- Innovative curriculum will empower providers to deliver
outcomes with excellence and support loyal patient
relationships
IRVINE,
Calif., Feb. 12, 2025 /PRNewswire/
-- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today
announced Allergan Medical Institute (AMI) will open three new
state-of-the-art training centers in the U.S. expanding access to
high-quality, tailored training to licensed aesthetics providers.
AMI's unique curriculum, designed to accelerate the science and art
of aesthetics, paired with the company's outstanding portfolio of
products, empowers providers and business owners to deliver desired
patient outcomes and experiences.
"The new AMI Training Centers are designed to help expand
and elevate our existing best-in-class training programs," said
Glen Curran, Senior Vice President,
U.S., Allergan Aesthetics. "The facilities will offer a range of
courses for providers at every stage of learning helping them to
safely and effectively deliver excellent outcomes and increase
patient satisfaction."
Since its first aesthetic approval for BOTOX®
Cosmetic (onabotulinumtoxinA), Allergan Aesthetics has led the
industry, ensuring excellence in training to empower aesthetic
providers to deliver safe, natural-looking results for their
patients. AMI is committed to elevating the science and art of
aesthetics through high-impact educational programs to aesthetic
providers that enable them to advance their capabilities. With the
new U.S. centers, AMI Training Centers will operate in more than
ten locations globally.
DRIVING INNOVATION IN TRAINING
The new AMI Training
Centers, strategically built in key markets, will leverage top
innovations in products, clinical education, techniques, and
technologies to drive continued growth and progress across the
aesthetic market. The offerings are focused on delivering safe and
desirable patient outcomes and helping aesthetic practices to
create lasting business success for themselves through patient
acquisition and satisfaction.
The Centers will feature AMI faculty trainers offering engaging
hands-on curriculum and an unparalleled learning experience for
providers and business managers, regardless of where they are in
their learning journey. The AMI Training Centers, presided over by
AMI Medical Director Dr. Saami Khalifian, are designed to enhance
the clinical techniques, complications management expertise, and
business acumen of participants. Trainees will gain the tools,
skills, and confidence needed to continue their journey as
aesthetic professionals, while building a community of mentors and
peers to help foster ongoing success.
"I've been actively involved in bringing these training centers
to life—working closely to develop innovative solutions, refine
ideas, and guide these concepts from vision to reality. It's an
honor to offer such a groundbreaking training experience to
professionals nationwide," said Dr. Saami Khalifian, Double
Board-Certified Dermatologist and Medical Director
AMI Training Centers. "Allergan Aesthetics leads the industry
in medical education by continually investing in robust programs
that set a new standard for excellence. These Centers exemplify
that commitment in ways unlike anything providers have seen before.
My hope is that every participant leaves feeling empowered,
equipped, and inspired to reach their highest potential faster than
they ever thought possible."
CONTINUED EXCELLENCE IN EDUCATION
Developed in
partnership between Allergan Aesthetics and expert healthcare
professionals, programming is high-caliber and intended to advance
scientific knowledge and technical skills in a variety of formats
including hands-on training, roundtable forums, national symposia,
live webcast events, exclusive resources, and a robust online
learning program, AMI online.
In November 2024, Allergan
Aesthetics launched AMI Business Education to the AMI online
learning platform to provide free courses to practitioners with
business operations education.
The first training center, AMI Orange County, located at
Allergan Aesthetics Headquarters in Irvine, Calif. is scheduled to open in 2025.
Additional locations in Atlanta
and Austin to follow. To learn
more about the training centers, please
visit: trainingcenters.amionline.com.
About Allergan Aesthetics
At Allergan Aesthetics, an
AbbVie company, we develop, manufacture, and market a portfolio of
leading aesthetics brands and products. Our aesthetics portfolio
includes facial injectables, body contouring, plastics, skin care,
and more. Our goal is to consistently provide our customers with
innovation, education, exceptional service, and a commitment to
excellence, all with a personal touch. For more information,
visit www.AllerganAesthetics.com.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines and solutions that solve serious
health issues today and address the medical challenges of tomorrow.
We strive to have a remarkable impact on people's lives across
several key therapeutic areas – immunology, oncology, neuroscience,
and eye care – and products and services in our Allergan Aesthetics
portfolio. For more information about AbbVie, please visit us at
www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X
(formerly Twitter), and YouTube.
About Allergan Medical Institute (AMI)
AMI is the
training arm of Allergan Aesthetics, delivering on its commitment
to excellence in aesthetics education. AMI empowers aesthetics
providers and business owners with innovative training offerings
across Allergan Aesthetics robust portfolio of products to maximize
educational impact and elevate the standard of exemplary patient
experiences. For more information visit
https://us.allerganmedicalinstitute.com/us/en/splash-page.html.
About AMI Online
AMI Online is a comprehensive
learning platform featuring in-depth education and training on the
Allergan Aesthetics Portfolio of Products available on demand,
24/7. It is designed to provide an adaptable, personalized learning
experience that helps injectors of all levels further their
knowledge, refine their skills, and advance their
expertise. AMI Online enables injectors and their staff to
review injection techniques, test their knowledge, earn
certificates, and stay up to date with upcoming educational events.
Allergan Medical Institute® Faculty offer expert training through
engaging, personalized content available to all AMI Online members
for free.
BOTOX® Cosmetic (onabotulinumtoxinA) Indications
and Important Safety Information
Indications
BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in
adult patients for the temporary improvement in the appearance
of:
- Moderate to severe glabellar lines associated with corrugator
and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with
orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis
activity
- Moderate to severe platysma bands associated with platysma muscle
activity
SAFETY CONSIDERATIONS
|
WARNING: DISTANT
SPREAD OF TOXIN EFFECT
Postmarketing
reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin
products may spread from the area of injection to produce symptoms
consistent with botulinum toxin effects. These may include
asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia,
dysphonia, dysarthria, urinary incontinence, and breathing
difficulties. These symptoms have been reported hours to weeks
after injection. Swallowing and breathing difficulties can be life
threatening and there have been reports of death. The risk of
symptoms is probably greatest in children treated for spasticity,
but symptoms can also occur in adults treated for spasticity and
other conditions, particularly in those patients who have an
underlying condition that would predispose them to these symptoms.
In unapproved uses and approved indications, cases of spread of
effect have been reported at doses comparable to those used to
treat cervical dystonia and spasticity and at lower
doses.
|
CONTRAINDICATIONS
BOTOX® Cosmetic is
contraindicated in the presence of infection at the proposed
injection site(s) and in individuals with known hypersensitivity to
any botulinum toxin preparation or to any of the components in the
formulation.
WARNINGS AND PRECAUTIONS
Seek immediate medical
attention if respiratory, speech, or swallowing difficulties occur.
The potency Units of BOTOX® Cosmetic are not equivalent
to other preparations of botulinum toxin products. Potential
serious adverse reactions have been reported after
BOTOX® Cosmetic injections for unapproved uses.
Concomitant neuromuscular disorder may exacerbate clinical effects
of treatment. Use with caution in patients with compromised
respiratory function.
DRUG INTERACTIONS
Patients receiving concomitant
treatment of BOTOX® Cosmetic and aminoglycosides or
other agents interfering with neuromuscular transmission (eg,
curare-like agents), or muscle relaxants, should be observed
closely because the effect of BOTOX® Cosmetic may be
potentiated.
USE IN SPECIFIC POPULATIONS
There are no studies or
adequate data from postmarketing surveillance on the developmental
risk associated with use of BOTOX® Cosmetic in pregnant
women.
Please see full Prescribing Information including
Boxed Warning and Medication Guide.
Forward-Looking Statements
Some statements in this news release are, or may be considered,
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. The words "believe," "expect,"
"anticipate," "project" and similar expressions and uses of future
or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2023 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
U.S. Media:
Ember Garrett
Communications and Public Relations
garrett_ember@allergan.com
Kate McShane
Corporate Communications
Kate.mcshane@allergan.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-to-launch-three-new-state-of-the-art-training-centers-in-the-us-expanding-access-to-high-quality-aesthetics-training-302374118.html
SOURCE AbbVie
